Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.64 |
| ▸ | CCR3 | P51677 | 20/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 17/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282383 | 0.90 | GPR119 (0.59) | HRH1CCR3KCNH2 | |
| SCHEMBL3948076 | 0.88 | HRH1 (0.59) | HRH1CCR3KCNH2 | |
| SCHEMBL5189718 | 0.87 | HRH1 (0.68) | HRH1CCR3KCNH2 | |
| SCHEMBL5462103 | 0.86 | GPR119 (0.58) | HRH1CCR3KCNH2 | |
| SCHEMBL6242779 | 0.85 | HRH1 (0.72) | HRH1CCR3KCNH2 | |
| SCHEMBL4720822 | 0.84 | HRH1 (0.62) | HRH1CCR3KCNH2 | |
| SCHEMBL5737424 | 0.84 | HRH1 (0.60) | HRH1CCR3KCNH2 | |
| SCHEMBL4968306 | 0.84 | HRH1 (0.66) | HRH1CCR3KCNH2 | |
| SCHEMBL5194856 | 0.83 | HRH1 (0.77) | HRH1CCR3KCNH2 | |
| SCHEMBL5194646 | 0.83 | CCR3 (0.47) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620400-B1 | piperidinylmethylpiperidine derivatives and their use as chemokine modulators | ASTRAZENECA AB (SE) | 2012-12-05 | — | — | EP | disclosed |
| US-20090118513-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-7495013-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-02-24 | — | — | US | disclosed |
| US-20080262037-A1 | Piperidine Derivatives for the Treatment of Chemokine Mediated Disease | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| EP-1625114-B1 | Piperidine derivatives for the the treatment of chemokine or H1 mediated diseases | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| EP-1816123-A1 | Intermediates for the production of pharmaceutically active compounds | AstraZeneca AB (SE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1546130-B1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| US-20070032523-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1735298-A1 | PIPERIDINE DERIVATES FOR THE TREATMENT OF CHEMOKINES MEDIARED DISEASE | AstraZeneca AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| US-20060281726-A1 | Piperidine derivatives for the treatment of chemokine or h1 mediated disease state | ASTRAZENECA AB (SE) | 2006-12-14 | — | — | US | disclosed |
| US-20060264463-A1 | Chemical compounds | MEDTECH CONVERGENCE FUND, L.P. | 2006-11-23 | — | — | US | disclosed |
| CN-1768037-A | Chemical compounds. | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | CN | disclosed |
| US-20060040984-A1 | Novel piperidine derivatives for use in the treatment of chemokine medicated disease states | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| EP-1620400-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1611124-A1 | PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CHEMOKINE OR H1 MEDIATED DISEASE STATE | AstraZeneca AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005097775-A1 | PIPERIDINE DERIVATES FOR THE TREATMENT OF CHEMOKINES MEDIARED DISEASE | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | WO | disclosed |
| WO-2004087659-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004085423-A1 | PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CHEMOKINE OR H1 MEDIATED DISEASE STATE | ASTRAZENECA AB (SE) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281726-A1 | Piperidine derivatives for the treatment of chemokine or h1 mediated disease state | CCR3, CCR1, CCL11 | HRH1 23/4885CCR3 1/4885KCNH2 2332/4885 |
| US-20090118513-A1 | Chemical Compounds | CCR3, CCR1, CCR4 | HRH1 38/4885CCR3 1/4885KCNH2 4039/4885 |
| US-20070032523-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 35/4885CCR3 1/4885KCNH2 3562/4885 |
| US-20060264463-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 38/4885CCR3 1/4885KCNH2 4041/4885 |
| US-20060040984-A1 | Novel piperidine derivatives for use in the treatment of chemokine medicated disease states | CCR3, CCR1, CCL11 | HRH1 49/4885CCR3 1/4885KCNH2 3450/4885 |
| US-20080262037-A1 | Piperidine Derivatives for the Treatment of Chemokine Mediated Disease | CCR3, CCR1, CCR4 | HRH1 51/4885CCR3 1/4885KCNH2 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.